Oncology & Cancer

Immunotherapy effective against some types of sarcoma

An existing cancer immunotherapy drug reduces tumor size in some types of rare connective tissue cancers, called sarcomas, report researchers at the University of Pittsburgh Cancer Institute (UPCI). Additional analyses of ...

Oncology & Cancer

Ipsilateral breast event risk higher over time with DCIS

(HealthDay)—The risks of developing an ipsilateral breast event (IBE) and an invasive IBE increased over time for patients with ductal carcinoma in situ (DCIS) who were selected on the basis of favorable clinical and pathologic ...

Immunology

Call for help to killer cells improves cancer rejection

Sometimes it takes a long time to solve a puzzle: In 1893, German surgeon G. Reinbach discovered that tumor tissue is often infiltrated by special cells of the immune system called eosinophils. Ever since then, scientists ...

Oncology & Cancer

SABCS: Genetic test may help predict DCIS recurrence

(HealthDay)—For women who have ductal carcinoma in situ surgically removed, a genetic test may help predict the odds of a recurrence, according to research presented at the annual San Antonio Breast Cancer Symposium, held ...

Oncology & Cancer

Study reveals optimal particle size for anticancer nanomedicines

Nanomedicines consisting of nanoparticles for targeted drug delivery to specific tissues and cells offer new solutions for cancer diagnosis and therapy. Understanding the interdependency of physiochemical properties of nanomedicines, ...

Oncology & Cancer

Yeast studies suggest alternative cancer approach

Yeast populations exposed to a sudden environmental shock can be driven to extinction, MIT researchers have shown. Could this principle also apply to human cancer cells? Possibly, argue researchers from MIT, Boston University, ...

page 4 from 9